 This statistic displays the projected top 20 products for neurology diseases based on revenue in the United States during 2016. In that year, Abilify, an Otsuka product, is expected to generate approximately 322 million U.S. dollars in revenues, a decrease of some 1.7 billion dollars compared to 2014, caused by patent loss. 